





We would like to add some remarks to the
report of a consensus meeting about
faecal microbiota transplantation (FMT)
by Cammarota et al.1
Already, donor faeces banks exist at an
institutional or national level in Germany,
UK and The Netherlands, to support
treatment of patients with recurrent
Clostridium difficile infection (CDI).2
Unfortunately, these centres were not con-
sulted for advice, and it is felt that some
conclusions of the report need clarifica-
tion and adjustments.
First, the statement about expert
centres is inaccurate. The critical steps for
safe and effective FMT are (1) patient
selection, (2) donor (stool) selection and
screening, and (3) biobanking of faeces
suspensions. We agree that donor screen-
ing should be performed by expert
centres in which microbiologists and
infectious disease specialists participate.
However, infusion of a donor faeces solu-
tion through a nasoduodenal tube, via col-
onoscopy or by enema does not justify
standard referral of patients with recur-
rent CDI to a specialised centre.
Whenever possible, this should even be
discouraged to prevent unnecessary
secondary spread of C. difficile.3
Second, the consensus report mentions
advantages of the use of frozen donor
faeces. Unfortunately, the authors do not
mention one of its most important advan-
tages, which is the potential of storage
until the donor has been retested prior to
actual use of the donor faeces. Retesting
precludes the possibility of missing newly
acquired pathogens in donor faeces during
the window phase between initial testing
and donation. We have experienced the
appearance of Blastocystis spp, rotavirus
and Extended Spectrum Beta-Lactamase
(ESBL)-positive Escherichia coli in the
stool of asymptomatic donors on retesting.
With support of a national grant from
ZonMw, the non-profit ‘Netherlands
Donor Feces Bank’ (NDFB, http://www.
ndfb.nl) was founded to overcome the
above problems and to ensure the availabil-
ity of extensively screened donor faeces
samples for patients that may benefit from
FMT.4 The working group consists of
experts in the fields of microbiology,
infectious diseases, gastroenterology, bio-
banking and methodology, and has exten-
sive experience with FMT.5 The voluntary
donors are carefully selected and screened.
Donor faeces is processed to ready-to-use
faecal suspensions (200 mL) and stored in a
biobank. Per suspension, 60 g of donor
faeces is used because a previous systematic
review suggested a decreased response rate
with <50 g.6 Only after retesting of the
donor, suspensions are sent out to physi-
cians in hospitals throughout The
Netherlands for treatment of patients with
recurrent or severe CDI. Before sending
out the donor faeces suspensions, the
working group is consulted on the indica-
tion, and in specific patients, on the mode
of delivery. In this way, expert advice is
ensured for each individual patient that is
treated with donor faeces suspensions of
the NDFB. The NDFB stores faeces
samples of each donor faeces suspension
that is used to guarantee traceability in case
of unexpected side effects and collects data
about long-term outcome.
In conclusion, a (centralised) stool
bank optimises the safety of FMT and
permits the infusion of donor faeces
solutions to individual patients in local
hospitals.
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